A recent ruling from the District Court for the District of Columbia has significant implications for medical school applicants across the United States. The court partially sided with Nirvana Durbal, who sued the Association of American Medical Colleges (AAMC), claiming that the fees charged for medical school applications violate antitrust and consumer protection laws. This case, filed under Civil Action No. 2025-2537, raises important questions about the fairness of application fees in the competitive landscape of medical education.
The ruling matters because it addresses whether the pricing practices of AAMC, which oversees the centralized application platform used by most U.S. medical schools, unfairly restricts competition. Durbal's case highlights concerns that the fees charged for applying to medical schools may be excessively high, potentially harming applicants financially.
Background
Nirvana Durbal is the plaintiff in this case, while the defendant is the AAMC, a nonprofit organization that represents all accredited medical schools in the United States. The AAMC developed the American Medical College Application Service (AMCAS), a centralized platform that allows applicants to submit their primary applications to multiple medical schools. More than 90% of U.S. medical schools require applicants to use AMCAS, which charges fees for processing applications.
Durbal applied to eleven medical schools through AMCAS during the 2024 application cycle, paying a total of $625 in primary application fees. She claims that these fees are unreasonably high and have been set in a manner that violates antitrust laws, specifically the Sherman Antitrust Act. Durbal's lawsuit seeks to represent a class of individuals who have paid similar fees to AAMC.
The case reached the District Court after AAMC filed a motion to dismiss Durbal's claims, arguing that she had not sufficiently stated a valid claim. The court was tasked with determining whether Durbal's allegations warranted further legal proceedings.
The Ruling
The court ruled in favor of Durbal in part, allowing her claim for unlawful restraint of trade in the medical doctor education market to proceed. However, it dismissed her claims related to the market for medical school primary application platforms and unfair trade practices under the D.C. Consumer Protection Procedures Act.
The court stated, "Durbal has plausibly alleged that AAMC's uniform pricing of primary application fees is an unreasonable restraint of trade in the medical doctor education market under the rule of reason, in violation of Section 1 of the Sherman Antitrust Act."
Judge Amir H. Ali presided over the case and emphasized the importance of assessing the effects of AAMC's pricing practices on competition within the medical education market. The court found that Durbal's allegations regarding the high fees charged for applications could indicate anticompetitive behavior, warranting further examination.
Impact
This ruling has significant implications for medical school applicants and the AAMC. If the case proceeds, it could lead to changes in how application fees are structured, potentially making the application process more affordable for students. The court's decision to allow Durbal's claim for unlawful restraint of trade to move forward suggests that there may be merit to the argument that AAMC's pricing practices could harm competition and applicants.
The ruling may also set a precedent for future cases involving pricing practices in educational services. If Durbal ultimately prevails, it could encourage other plaintiffs to challenge similar practices in various educational sectors, potentially leading to broader reforms in how educational institutions charge fees.
What's Next
The case is not over, as AAMC may choose to appeal the court's decision regarding Durbal's claim for unlawful restraint of trade. Additionally, there may be related cases pending that could further address antitrust issues in the education sector. As the legal proceedings continue, stakeholders in the medical education field will be closely watching the developments.